Author

Laurent Claret

Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics

2009 · Laurent Claret, Pascal Girard, et al. · Journal of Clinical Oncology · 272

Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma

2016 · M Stroh, H Winter, et al. · Clinical Pharmacology & Therapeutics · 156

Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer

2013 · Laurent Claret, Manish Gupta, et al. · Journal of Clinical Oncology · 135

Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials

2014 · R Bruno, F Mercier, et al. · Clinical Pharmacology & Therapeutics · 72

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics

2018 · Laurent Claret, Jin Y. Jin, et al. · Clinical Cancer Research · 69

On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies

2009 · R Bruno, L Claret · Clinical Pharmacology & Therapeutics · 46

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer

2011 · N. Frances, L. Claret, et al. · Cancer Chemotherapy and Pharmacology · 45

Simulations Using a Drug–Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non–Small-Cell Lung Cancer

2012 · L Claret, J-F Lu, et al. · Clinical Pharmacology & Therapeutics · 34

A Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain

2014 · François Mercier, Laurent Claret, et al. · Pain and Therapy · 31

PDF

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer

2010 · Laurent Claret, Jian-Feng Lu, et al. · Cancer Chemotherapy and Pharmacology · 30

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients

2010 · Jian-Feng Lu, Laurent Claret, et al. · Cancer Chemotherapy and Pharmacology · 28

Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients

2015 · Laurent Claret, Francois Mercier, et al. · Cancer Chemotherapy and Pharmacology · 26

A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

2010 · Rene Bruno, Jian-Feng Lu, et al. · The Journal of Clinical Pharmacology · 26

Fractal Volume of Drug Distribution: It Scales Proportionally to Body Mass

2001 · Vangelis Karalis, Laurent Claret, et al. · Pharmaceutical Research · 22

A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use

2015 · F Jonsson, Y Ou, et al. · CPT Pharmacometrics & Systems Pharmacology · 19

PDF

Exploratory Modeling and Simulation to Support Development of Motesanib in Asian Patients With Non–Small Cell Lung Cancer Based on MONET1 Study Results

2014 · L Claret, R Bruno, et al. · Clinical Pharmacology & Therapeutics · 19

Model-Based Drug Development in Oncology: What’s Next?

2013 · R Bruno, F Mercier, et al. · Clinical Pharmacology & Therapeutics · 19

Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first‐line non‐small cell lung cancer treated with chemotherapy with or without bevacizumab

2013 · Laurent Claret, Manish Gupta, et al. · The Journal of Clinical Pharmacology · 18

Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent

2006 · L. Claret, P. Girard, et al. · Journal of Clinical Oncology · 18

Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer

2012 · R Bruno, L Lindbom, et al. · CPT Pharmacometrics & Systems Pharmacology · 17

PDF

Modeling and Simulation of Sexual Activity Daily Diary Data of Patients with Female Sexual Arousal Disorder Treated with Sildenafil Citrate (Viagra®)

2006 · Laurent Claret, Eugene H. Cox, et al. · Pharmaceutical Research · 16

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A

2016 · Kelong Han, L Claret, et al. · CPT Pharmacometrics & Systems Pharmacology · 15

PDF

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study

2018 · Laurent Claret, Christina Pentafragka, et al. · Cancer Chemotherapy and Pharmacology · 14

A Stochastic Model Describes the Heterogeneous Pharmacokinetics of Cyclosporin

2001 · Laurent Claret, Athanassios Iliadis, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 13

Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response

2011 · Rene Bruno, Fredrik Jonsson, et al. · Blood · 12

Works count: 63

Citation count: 1,246

H-index: 18

I10-index: 26